Article

Alfa Chemistry Enriches API Supply by Adding Lenalidomide, Parecoxib Sodium, and Rivaroxaban

Topic: Business DevelopmentPublished December 23, 2022

Legacy signals

Legacy popularity: 303 legacy views

As one of the leading chemical manufacturers and suppliers globally, Alfa Chemistry is well-prepared to provide a number of active pharmaceutical ingredients (APIs), such as donepezil and dexmedetomidine hydrochloride, for customers worldwide ranging from lab to commercial scale. Earlier this month, the company announced that three other APIs had been introduced for its global customers as well, namely, lenalidomide, parecoxib sodium, and rivaroxaban. “With highly skilled Ph.D. and M.S. synthetic chemists as well as advanced technological facilities, we are able to meet the highest manufacturing standards to synthesize innovative small molecular APIs for pharmaceutical companies across the world,” said the Marketing Chief of Alfa Chemistry. “Throughout the manufacturing process, we focus extensively on the safety of API production on the one hand and pay attention to ensure all quality standards and cGMP requirements are met on the other.” LenalidomidernThe lenalidomide API provided by Alfa Chemistry can be used in research applications or medication production for the treatment of cancerous and anemia patients who are suffering from certain blood/bone marrow disorders. Lenalidomide, as an oral immunomodulatory drug, revealed a good safety profile. Parecoxib SodiumrnAlfa Chemistry offers high-quality parecoxib sodium as API to support the amide prodrug of the cyclooxygenase II (COX-2)-selective inhibitor, non-steroidal anti-inflammatory drug (NSAID) valdecoxib, which has anti-inflammatory, analgesic, and antipyretic activities. RivaroxabanrnRivaroxaban, as an antithrombotic drug, is widely used in the treatment and prevention of deep vein thrombosis (DVT) symptoms prior to hip or knee replacement surgery, treatment of venous thromboembolism (VTE) and nonvalvular atrial fibrillation, as well as treatment of DVT and pulmonary embolism (PE). Alfa Chemistry offers rivaroxaban for related research and manufacturing. All APIs provided by Alfa Chemistry meets the CP & EP standards. Please visit https://www.alfa-api.com/ to learn more.

Further reading

Further Reading

4 total

Article

Artificial intelligence continues to dominate business conversations, but enthusiasm alone does not guarantee results. While many companies rush to adopt AI in hopes of gaining a competitive edge, a large number of initiatives still fall short. The problem is rarely the technology itself. More often, failure happens because organizations approach AI without the structure, readiness, and discipline required for long-term success. AI projects do not fail because the technology

March 4, 2026

Article

AI Avatar Development: Real Innovation or Just Hype? In today’s hyperconnected world, attention is currency. To stand out, brands can no longer settle for flashy features or surface-level engagement. They need to build meaningful, scalable, and personalized experiences. Enter AI avatars: digital humans that are revolutionizing communication by bringing lifelike presence to virtual interactions. Imagine a team member who never takes a coffee break, speaks ten languages fluen

February 27, 2026

Article

The Quiet Engine Behind Every Connection Most people think of telecom services as towers, signals, and mobile data moving invisibly through the air. Yet behind every call that connects and every message that reaches its destination, there is another system quietly working in the background. That system is the call center. While customers often interact with telecom companies only when something goes wrong, these centers operate constantly, guiding problems toward solutions an

February 23, 2026

Article

Introduction The solar industry once believed that collecting as many leads as possible was the fastest path to growth. Marketing teams focused on filling databases with names, phone numbers, and email addresses. At first, the numbers looked promising. Dashboards showed rising interest and more inquiries than ever before. Yet behind the scenes, many companies began to notice a quiet problem. Revenue growth did not match the flood of leads. Sales teams felt overwhelmed, conver

February 6, 2026